在结直肠癌中,以分子分析为导向的个性化辅助疗法:弥合临床差异的共识指南
1Department of Colorectal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China. xfcheng@zju.edu.cn.
World journal of gastroenterology
|February 16, 2026
概括
分子分析正在改变结直肠癌 (CRC) 辅助疗法,超越传统的分期. 关键生物标志物可以改进风险和治疗,但实施缺口仍然存在,需要针对个性化护理的综合解决方案.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 精准医学是一门精准的医学.
背景情况:
- 结肠直肠癌 (CRC) 辅助疗法正在从基于阶段的方法转向以分子分析为指导的方法.
- 关键生物标志物对于完善CRC中的风险分层和治疗选择至关重要.
研究的目的:
- 审查生物标志物在CRC辅助治疗中的不断变化的作用.
- 识别实施缺陷,并为个性化CRC处理提出解决方案.
主要方法:
- 关于CRC生物标志物和辅助治疗 (2010-2025) 的综合文献搜索 (PubMed,科学网).
- 对关键生物标志物的分析:不匹配修复 (MMR) 状态,RAS突变,共识分子亚型和循环瘤DNA (ctDNA).
主要成果:
- 像MMR状态和ctDNA这样的生物标志物完善了CRC中的风险分层和治疗选择.
- 由于测试的变化,不断变化的证据和经济障碍,现实世界实施的差异仍然存在.
结论:
- 解决实施差距需要技术创新 (人工智能,多经济学,ctDNA监测),优化临床途径和支持性政策.
- 跨学科的合作对于将分子洞察力转化为公平,个性化的CRC患者辅助护理至关重要.
相关概念视频
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
15
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
15
Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Pharmacogenomics: Identification of New Drug Targets
9
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
9


